Clive Morris
Nessuna posizione attualmente
Profilo
Clive Morris worked as a Managing Director at CorpHQ, Inc. He was also an Investor Relations Contact at AstraZeneca PLC and President-Inivata at NeoGenomics, Inc. Morris was a Director at Inivata Ltd.
in 2022.
He holds a doctorate degree from The Royal College of Surgeons of England.
Precedenti posizioni note di Clive Morris
| Società | Posizione | Fine |
|---|---|---|
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Amministratore Delegato | 18/06/2021 |
| NEOGENOMICS, INC. | Corporate Officer/Principal | 30/06/2022 |
| CorpHQ, Inc. | Corporate Officer/Principal | 06/08/2007 |
| ASTRAZENECA PLC | Public Communications Contact | - |
Formazione di Clive Morris
| The Royal College of Surgeons of England | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| NEOGENOMICS, INC. | Health Services |
| Aziende private | 2 |
|---|---|
| CorpHQ, Inc. | Communications |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
- Borsa valori
- Insiders
- Clive Morris
